Diagnosis and management of benign prostatic hyperplasia

American Family Physician

Volumn 77, Issue 10, 2008, Pages

  Edwards, Jonathan L ^a  

^a Barberton Citizens Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; CERNITIN; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; GRASS POLLEN EXTRACT; OPIATE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PLANT EXTRACT; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; RYE GRASS POLLEN EXTRACT; SAW PALMETTO EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; STEROID 5ALPHA REDUCTASE;

AMBULATORY SURGERY; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; BEDTIME DOSAGE; BLADDER CANCER; BLADDER CATHETERIZATION; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEMATURIA; HISTORY; HUMAN; HYPERTENSION; HYPONATREMIA; INCONTINENCE; INTERVENTION STUDY; KIDNEY INJURY; LABORATORY TEST; LASER SURGERY; LIBIDO; LOWER URINARY TRACT SYMPTOM; MORBIDITY; NOCTURIA; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; PERIOPERATIVE PERIOD; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; STRICTURE; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; URINALYSIS; URINARY HESITANCY; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; AGED; ANAMNESIS; DRUG ANTAGONISM; EVIDENCE BASED MEDICINE; HOSPITALIZATION; MALE; METHODOLOGY; MIDDLE AGED; MINIMALLY INVASIVE SURGERY; MULTIMODALITY CANCER THERAPY; ORGANIZATION AND MANAGEMENT; PATIENT CARE PLANNING; PHYTOTHERAPY; PROSTATECTOMY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; PATIENT CARE PLANNING; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 45549091557     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Cotran RS, Kumar V, Robbins SL. Male genital system. In: Robbins Pathologic Basis of Disease. 5th ed. Philadelphia, Pa.: Saunders;1994.
2. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology. 1991;38(1 suppl):4-8.
3. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001;58(6 suppl 1):5-16. (Pubitemid 34007591)
4. Meigs JB, Barry MJ. Natural history of benign prostatic hyperplasia. In: Kirby R. Textbook of Benign Prostatic Hyperplasia. Oxford, U.K.: Isis Medical Media; 1996:125-135.
5. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Cambell MF, Walsh PC, Retic AB. Campbell's Urology. 8th ed. Philadelphia, Pa.: Saunders; 2002:1297-1330.
6. American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH). http://www.auanet.org/guidelines/bph.cfm. Accessed September 19, 2007.
7. McConnell JD, Roehrborn CG, Bautista OM, et al., for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398.
8. Roehrborn CG, Boyle P, Bergner D, et al., for the PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology. 1999;54(4):662-669. (Pubitemid 29449427)
9. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-589. (Pubitemid 29136206)
10. Logan YT, Belgeri MT. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2005;3(2):103-114. (Pubitemid 41200512)
11. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [published correction appears in JAMA. 2002;288(23):2976]. JAMA. 2000;283(15):1967-1975.
12. Lepor H, Williford WO, Barry MJ, et al., for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335(8):533-539.
13. McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Am J Med. 2005;118(12):1331-1339. (Pubitemid 41832322)
14. McConnell JD, Bruskewitz R, Walsh P, et al., for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557-563.
15. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year study. CMAJ. 1996;155(9):1251-1259.
16. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. (Pubitemid 36859473)
17. Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol. 1996;14(2 suppl 2):22-31. (Pubitemid 26157534)
18. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998;52(2):195-201.
19. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996;48(1):12-20. (Pubitemid 26255953)
20. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(3):CD001423.
21. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557-566. (Pubitemid 43209103)
22. Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042.
23. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044.
24. Hollingsworth JM, Wei JT. Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia. Rev Urol. 2006;(8 suppl 3):S9-S15.
25. Wilson LC, Gilling PJ, Williams A, et al. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50(3):569-573. (Pubitemid 44189064)
26. Shabbir M, Kirby R. Fact or fiction: what do the benign prostatic hyperplasia data tell us? Curr Urol Rep. 2005;6(4):243-250.
27. Roehrborn CG, Issa MM, Bruskewitz RC, et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study [published correction appears in Urology. 1998;52(1):159]. Urology. 1998;51(3):415-421. (Pubitemid 28136679)
28. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003;44(1):89-93. (Pubitemid 36741379)
29. Rosario DJ, Phillips JT, Chapple CR. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection when alpha-adrenergic antagonist therapy fails. J Urol. 2007;177(3):1047-1051. (Pubitemid 46216363)
30. Riehmann M, Knes JM, Heisey D, Madsen PO, Bruskewitz RC. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology. 1995;45(5):768-775.
31. Dull P, Reagan RW Jr, Bahnson RR. Managing benign prostatic hyperplasia. Am Fam Physician. 2002;66(1):77-84. (Pubitemid 34753365)
32. Agency for Health Care Policy and Research. Benign prostatic hyperplasia: diagnosis and treatment. Rockville, Md.: United States Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1994. AHCPR publication no. 94-0582.
33. Donovan JL, Peters TJ, Neal DE, et al. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: the CLasP study. J Urol. 2000;164(1):65-70. (Pubitemid 30434261)
34. Hoffman RM, MacDonald R, Wilt TJ. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. 2004;(1):CD001987.
35. Meng F, Gao B, Fu Q, et al. Change of sexual function in patients before and after Ho:YAG laser enucleation of the prostate. J Androl. 2007;28(2):259-261. (Pubitemid 46423908)
36. Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2001;165(5):1526-1532. (Pubitemid 32410231)
37. Mattiasson A, Wagrell L, Schelin S, et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology. 2007;69(1):91-96. (Pubitemid 46161719)